Hepatite crônica C. Novos tratamentos. Prof. Henrique Sergio Moraes Coelho. III Workshop Internacional de Atualização em Hepatologia
|
|
- Laurel Matthews
- 6 years ago
- Views:
Transcription
1 Hepatite crônica C Novos tratamentos Prof. Henrique Sergio Moraes Coelho III Workshop Internacional de Atualização em Hepatologia Abril de 2008 Curitiba-Paran Paraná
2 Hepatology
3 Real-World SVR Results Canadian Expanded-Access Program N=863, treated with PEG IFN alfa-2b QW + RBV 800 mg/d SVR (%) Naive, No Cirrhosis Naive, Cirrhosis PEG IFN, pegylated interferon; RBV, ribavirin; SVR, sustained virologic response Relapsers All Genotypes Genotype 1 Genotype Nonresponders Yoshida E, et al., DDW; May 14-19, Abstract S1572.
4 Necessidade de novas drogas para hepatite C Problemas com a terapia antiviral Peg/RBVl Requer injeções repetidas; Tempo de tratamento prolongado Efeitos colaterais são freqüentes e difíceis de aceitar em pacientes assintomáticos; Contra-indicações são freqüentes (20 30% dos candidatos); Metade dos pacientes não responde;
5 Quem serão os candidatos às novas terapias antivirais? a) Pacientes com cirrose hepática ; b) Pacientes co-infectados (C + HIV); c) No pós-transplante hepático; d) Nos recidivantes, após tratamento com PegINF/RBV; e) Não respondedores a PegInf/RBV(avaliar fatores preditivos) f) Pacientes com genótipo 1 com fatores preditivos de má resposta
6 Potenciais alvos das novas moléculas Inibidores de Protease Inibidores da Polimerase Kwong A, et al. Beyond interferon and ribavirin: Antiviral therapies for hepatitis C virus. Drug Discovery Today: Therapeutic Strategies. 2006;3:
7 Protease Inhibitor Telaprevir for Treatment of Hepatitis C
8 Telaprevir(VX 950) Selective, specific peptidomimetic inhibitor 14 days Most sustained viral suppression with 750 mg q8h ; highest trough levels Mean log drop 4.4 with 750 mg dosing Leveling off or rebound associated with identifiable mutations Even more profound viral suppression reported with PEG IFN (median 5.5 log) - Vertex press release Jan 8, 2006 Reesink HW, et al. Hepatology. 2005;42:234A.
9 Telaprevir Median HCV RNA Over Time 7 Median HCV RNA (Log 10 IU/mL) Resistance profiles established Study Time (Days) Placebo VX mg q8h VX mg q8h VX mg q12h Reesink HW, et al. DDW; May 14-19, Abstract 527.
10 Update on Investigational Agents in HCV: 2007 PROVE 1: Telaprevir + PegIFN/RBV in Treatment-Naive HCV GT 1 Patients Patients (%) SVR Rates in 12 and 24-Week Arms 12 wks TVR/pegIFN/RBV; 12 wks pegifn/rbv 12 wks TVR/pegIFN/RBV 61 Intent-to-treat Interim Analysis End-of-Treatment Response in 48-Week Arms 48 wks pegifn/rbv 12 wks TVR/pegIFN/RBV; 36 wks pegifn/rbv (n = 79) (n = 17) (n = 75) (n = 79) Jacobson I, et al. AASLD Abstract 177. clinicaloptions.com/hep
11 Update on Investigational Agents in HCV: 2007 PROVE 2: Telaprevir + PegIFN/RBV in Treatment-Naive HCV GT 1 Patients Wk 12 Interim Analysis Wk 24 Wk 36 Wk 48 Treatmentnaive patients infected with HCV genotype 1* (n = 323) Placebo + PegIFN alfa-2a 180 µg/wk + RBV mg QD (n = 82) Telaprevir 750 mg every 8 hrs + PegIFN alfa-2a + RBV (n = 81) Telaprevir 750 mg every 8 hrs + PegIFN alfa-2a + RBV (n = 82) Telaprevir 750 mg every 8 hrs + PegIFN alfa-2a (n = 78) PegIFN alfa-2a + RBV (n = 81) Follow-up Follow-up Follow-up *Patients received telaprevir 1250-mg loading dose or placebo based on the arm to which they were randomized. Patients received 12 or 24 weeks regardless of whether RVR occurred. Hezode C, et al. AASLD Abstract 80. clinicaloptions.com/hep
12 Update on Investigational Agents in HCV: 2007 PROVE 2: Telaprevir + PegIFN/RBV in Treatment-Naive HCV GT 1 Patients Outcome, % Undetectable HCV RNA Wk 4 Wk 12 Placebo + PegIFN + RBV (n = 82) TVR + PegIFN + RBV for 24 Wks (n = 81) SVR Ongoing Viral breakthrough * 73* TVR + PegIFN + RBV for 12 Wks (n = 82) 80* 79* TVR + PegIFN for 12 Wks (n = 78) *P <.001 vs pegifn/rbv/placebo arm. SVR at 12 wks posttreatment for 24-week arm; SVR at 24 wks posttreatment for 12-week and no-rbv arms. HCV RNA increase of > 1 log above the nadir, or increase to > 100 IU/mL in patients with previously undetectable HCV RNA. 51* 62* Hezode C, et al. AASLD Abstract 80. clinicaloptions.com/hep
13 Update on Investigational Agents in HCV: 2007 PROVE 2: Telaprevir + PegIFN/RBV in Treatment-Naive HCV GT 1 Patients Total adverse events leading to discontinuation during Weeks 1-12 Control: 5% 24-week arm: 15% 12-week arm: 13% No RBV arm: 10% Adverse Event, % Pruritus Grade 3 Nausea Grade 3 Rash, all types Grade 3 Insomnia Dyspnea Grade 3 Anemia Grade 3 Placebo + PegIFN + RBV (n = 81) Hezode C, et al. AASLD Abstract 80. TVR + PegIFN + RBV for 12/24 Wks (n = 163) < TVR + PegIFN for 12 Wks (n = 78) clinicaloptions.com/hep
14 Boceprevir (SCH ) Me Me Me Me Me H N O H N N Me Me Me O O O H N NH 2 O Dados In vitro K i * =14 nm elastase/hcv = 2000 Replicon IC 50 = 200 nm Replicon IC 90 = 400 nm (200 ng/ml) No inhibition of CYP Dados Farmacocinéticos Biodisponibilidade oral Distribuição Fígado/Plasma: ~30 Nenhum problema na estabilidade plasmática
15 Farmacodinâmica Boceprevir Estudo Monoterapia em Não Respondedores Médias de Redução em Log 10 HCV RNA 0,5 0-0,5-1 -1,5-2 Tratamento Follow-up Placebo 100 mg BID 200 mg BID 400 mg BID 400 mg TID Dias Após Início Tratamento Zeuzem et al. AASLD 2005
16 SCH Plus PEG IFN Antiviral Activity in Genotype 1 Nonresponders Mean HCV RNA Change (Log 10 ) Treatment Day PEG IFN alfa-2b Alone (n = 22) PEG IFN alfa-2b +SCH mg TID (n = 12) PEG IFN alfa-2b +SCH mg TID (n = 12) Zeuzem S, et al. Hepatology. 2005;42:233A.
17 SPRINT -1 Study N= 595 pacientes - Naive e Genótipo 1 Estados Unidos, Canadá e Europa 77% americanos 16% Afro-americanos 7% cirróticos
18 HCV SPRINT-1 Study - Fase II Pacientes Naïve G1 Arm 1 Boceprevir 800mg TID + PegIntron (1,5mcg/kg/sem) + Rebetol ( mg/dia) Boceprevir 800mg TID + PegIntron + Rebetol 28 Weeks 48 Weeks Follow-up 24 Weeks Follow-up 24 Weeks Screening Arm 2 PegIntron + Ribavirin 4 Semanas Boceprevir 800mg TID +PegIntron + Rebetol Boceprevir 800mg TID + PegIntron + Rebetol 44 Weeks Follow-up 24 Weeks Follow-up 24 Weeks 24 Weeks Arm 3 Arm 4 Boceprevir 800 mg TID + PegIntron (1,5mcg/kg/sem) + low dose Rebetol ( mg/dia) 48 Semanas PegIntron (1,5mcg/kg/sem) + Rebetol ( mg/dia) 48 Semanas Follow-up 24 Weeks Follow-up 24 Weeks
19 Resultados RVPc Semana % 80% 70% 79% 60% 40% 54% 34% RVPc - PCR negativo na semana 12 (<15UI/ml) 20% 0% Grupo 1 Grupo 2 Grupo 3 Grupo 4
20 Polymerase Inhibitors for Hepatitis C
21 Update on Investigational Agents in HCV: 2007 Polymerase Inhibitor R1626 in Treatment-Naive Genotype 1 Patients Interim results of multicenter, randomized, active-controlled, double-blind, phase IIa trial Wk 4 interim analysis Wk 48 Treatmentnaive patients with HCV genotype 1 infection (N = 104) PegIFN alfa-2a 180 µg/wk + RBV mg QD (n = 20) R mg BID + PegIFN PegIFN + RBV (n = 21) R mg BID + PegIFN PegIFN + RBV (n = 32) R mg BID + PegIFN + RBV PegIFN + RBV (n = 31) Pockros PJ, et al. AASLD Abstract week follow-up clinicaloptions.com/hep
22 Update on Investigational Agents in HCV: 2007 Polymerase Inhibitor R1626 for Treatment-Naive Genotype 1 Patients Mean HCV RNA Reduction at Wk 4 Undetectable HCV RNA at Wk 4 PegIFN/RBV R /pegIFN R /pegIFN R /pegIFN/RBV Log 10 IU/mL HCV RNA Patients (%) Pockros PJ, et al. AASLD Abstract 167. clinicaloptions.com/hep
23 Update on Investigational Agents in HCV: 2007 Polymerase Inhibitor R1626 for Treatment-Naive Genotype 1 Patients No emergence of R1626 resistance detected Gastrointestinal adverse effects common with R1626, particularly in 3000 mg dosing arm Cytopenias, especially neutropenia, commonly associated with R1626 Neutropenia not associated with increased incidence of infection Week 4 Cumulative Laboratory Abnormalities, n (%) Neutropenia Grade 3 Grade 4 Thrombocytopenia Grade 3/4 Anemia Grade 1/2 Grade 3/4 R mg + PegIFN (n = 21) 8 (38) 10 (48) 2 (10) 0 (0) 0 (0) Pockros PJ, et al. AASLD Abstract 167. R mg + PegIFN (n = 32) 5 (16) 25 (78) 15 (47) 3 (9) 0 (0) R mg + PegIFN/RBV (n = 31) 16 (52) 12 (39) 4 (13) 10 (32) 3 (10) PegIFN/RBV (n = 20) 6 (30) 2 (10) 0 (0) 1 (5) 0 (0) clinicaloptions.com/hep
24 Treatment With Nitazoxanide for Hepatitis C
25 Update on Investigational Agents in HCV: 2007 Nitazoxanide-Based Therapy for HCV Genotype 4-Infected Patients STEALTH C-1: phase II, randomized, controlled trial of nitazoxanide in HCV Nitazoxanide: a thiazolide with in vitro activity against HBV and HCV Approved for treatment of diarrhea caused by Giardia and Cryptosporidium SVR12 Wk 12 Wk 48 Wk 60 HCV GT 4 patients from 2 sites in Egypt Nitazoxanide 500 mg BID (n = 40)* PegIFN alfa-2a 180 μg/wk + RBV mg QD (n = 40 [all interferon naive]) Nitazoxanide 500 mg BID + PegIFN alfa-2a 180 μg/wk Follow-up Follow-up (N = 120) Nitazoxanide 500 mg BID (n = 40)* Nitazoxanide 500 mg BID + PegIFN alfa-2a 180 μg/wk + RBV mg QD *n = 28 interferon-based regimen naive; 12 interferon-based regimen experienced. Rossignol JF, et al. AASLD Abstract 178. Follow-up clinicaloptions.com/hep
26 Update on Investigational Agents in HCV: 2007 Nitazoxanide-Based Therapy for HCV Genotype 4-Infected Patients (cont d) ITT Analysis in Interferon-Naive Patients: SVR12 in treatment-experienced HCV RNA Negative* During Combination Therapy patients PegIFN/RBV Nitazoxanide/ Nitazoxanide/ Nitazoxanide + pegifn + RBV: 25% pegifn pegifn/rbv Nitazoxanide + pegifn: 8% 100 P = Discontinuations during therapy in treatment-naive patients Nitazoxanide + pegifn: 18% 43 Nitazoxanide + pegifn + RBV: 14% PegIFN + RBV: 18% Patients (%) 20 0 Wk 4 Wk 12 ETR SVR 12 *HCV RNA < 10 IU/mL. Nitazoxanide generally well tolerated Grade 3 neutropenia more common in nitazoxanide-containing arms Rossignol JF, et al. AASLD Abstract 178. clinicaloptions.com/hep
27 HCV Treatment Update Phase II Study: Eltrombopag Increased Platelet Counts at All Doses Evaluated Significantly more patients with HCV-associated thrombocytopenia achieved 100,000 cells/μl at Week 4 in all eltrombopag dose groups compared with placebo (P.0003) Treatment Week Baseline Week 4 Placebo 55 (27-75) 53 (34-74) Median Platelet Count, x 10 3 /µl (Range) Eltrombopag 30 mg/day 59 (34-94) 137 (40-528) Eltrombopag 50 mg/day 52 (26-66) 214 (47-499) Eltrombopag 75 mg/day 54 (28-75) 209 (78-527) Best responses with eltrombopag 75 mg/day 91% of this group able to initiate HCV therapy 65% of this group able to complete 12 weeks of therapy McHutchinson JG, et al. AASLD Abstract LB3. clinicaloptions.com/hep
28 New Interferon Formulations for Hepatitis C
29 Update on Investigational Agents in HCV: 2007 Albinterferon alfa-2b in Treatment- Naive Genotype 1 Patients (cont d) HCV RNA Negative, % Wk 4 Wk 12 Wk 48 SVR PegIFN + RBV (n = 114) AlbIFN 900 µg Every 2 Wks + RBV (n = 118) Among adherent patients weighing 75 kg, albifn 900 μg every 2 wks + RBV achieved a higher rate of SVR vs pegifn + RBV: 74.2% vs 53.3% Significant predictors of SVR (pooled all groups) % adherence to therapy vs < 80% adherence: 67% vs 39% (P <.001) Baseline ALT > 3 x ULN vs < 3 x ULN: 66% vs 54% (P <.001) HCV RNA < 400,000 IU/mL vs > 400,000 IU/mL: 76% vs 48% (P <.001) Gamma glutamyltransferase < ULN vs ULN: 62% vs 42% (P <.001) Zeuzem S, et al. AASLD Abstract 180. AlbIFN 1200 µg Every 2 Wks + RBV (n = 110) AlbIFN 1200 µg Every 4 Wks + RBV (n = 116) clinicaloptions.com/hep
30 STAT-C Likely Picture - Near Future Viral enzyme inhibitors RBV or ± ± related drugs Immune modulation Interferon as a platform for future combinations Duration of treatment?dosis?other combinations?
New Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD
Viral Targets for HCV New Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD Sites for development of inhibitors Metalloproteinase Serine protease (trans) Core E E2 NS2 NS3 NS4a/NS4b NS5a/NS5b
More informationةي : لآا ةرقبلا ةروس
سورة البقرة: اآلية HCV RELAPSERS AND NONRESPONDERS: How to deal with them? BY Prof. Mohamed Sharaf-Eldin Prof. of Hepatology and Gastroenterology Tanta University Achieving SVR The ability to achieve a
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationHepatitis C Therapy Falk Symposium September 20, 2008
Hepatitis C Therapy Falk Symposium September 20, 2008 Ira M. Jacobson, MD Vincent Astor Professor of Clinical Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C
More informationSimeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial
Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More informationClinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.
Clinical Cases Hepatitis C Naïve Patients Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Case study 1 27 year old woman, Diagnosed with Chronic Hepatitis C 3 years ago
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More informationInterferon Side Effects and The Future of Interferon Sparing Regimens. Todd Wills, MD ETAC Infectious Disease Specialist
Interferon Side Effects and The Future of Interferon Sparing Regimens Todd Wills, MD ETAC Infectious Disease Specialist HEPATITIS C TREATMENT EXPANSION INITIATIVE MULTISITE CONFERENCE CALL FEBRUARY 15,
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationThe HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany
: Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Goals for Hepatitis C Therapy Compared to PegIFN α/rbv, new treatment regimens for chronic hepatitis C should offer: Improved efficacy Efficacy
More informationV.G. Bain, P. Marotta, K. Kaita, E. Yoshida, M. Swain, R. Bailey, A. Neumann, P. Cronin, J. McHutchison, E. Pulkstenis, M.
COMPARABLE ANTIVIRAL RESPONSE RATES WITH ALBINTERFERON ALFA-2B DOSED AT Q2W OR Q4W INTERVALS IN NAIVE SUBJECTS WITH GENOTYPE 2 OR 3 CHRONIC HEPATITIS C V.G. Bain, P. Marotta, K. Kaita, E. Yoshida, M. Swain,
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More informationHCV MEDICATIONS & Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati
HCV MEDICATIONS & THERAPEUTIC TRIALS Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati DISCLOSURES Active or Within 12 Months Research
More informationHIV and Hepatitis C: Advances in Treatment
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and Hepatitis C: Advances in Treatment John Scott, MD, MSc Asst Professor University of Washington Presentation prepared & presented by: John Scott, MD,
More informationViral hepatitis in reproductive health. Pierre Jean Malè. Training in Reproductive Health Research - Geneva 2006
Viral hepatitis in reproductive health Pierre Jean Malè Training in Reproductive Health Research - Geneva 2006 15.03.2006 HBV and HCV treatment Pierre-Jean Malè MD 15.03.2006 Global Impact of Hepatitis
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationLes Inhibiteurs de Protéase du VHC
Les Inhibiteurs de Protéase du VHC Pr Jean-Michel Pawlotsky National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
More informationVII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
More informationHighlights of AASLD 2012 CCO Official Conference Coverage of the 2012 Annual Meeting of the American Association for the Study of Liver Diseases
Highlights of AASLD 12 CCO Official Conference Coverage of the 12 Annual Meeting of the American Association for the Study of Liver Diseases November 9-13, 12 Boston, Massachusetts In partnership with
More informationVirological Tools and Monitoring in the DAA Era
Virological Tools and Monitoring in the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationDirect acting anti-virals: the near future
Direct acting anti-virals: the near future Heiner Wedemeyer Hannover Medical School Germany Will IFN-free treatment be possible in the near future? Interferon-free regimens to treat hepatitis C What should
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationTratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona
Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona rrent HCV Therapy 8% % sustained response 6% 4% 2% % 54-61% 41% 34% 25% 16% 6% IFN 24w IFN 48w Peg
More informationHepatitis C Virus Treatments: Present and Future
Hepatitis C Virus Treatments: Present and Future Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Boehringer Ingelheim,
More informationABCs of Hepatitis C: What s New. The Long-Awaited New Era: Protease Inhibitors for HCV Genotype 1
ABCs of Hepatitis C: What s New ACG Postgraduate Course Washington, DC October 30, 2011 Ira M. Jacobson, M.D. Vincent Astor Professor of Medicine Chief, Division of Gastronterology and Hepatology Medical
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationENABLE 1 Study. To evaluate the safety and tolerability of eltrombopag Primary efficacy outcome: proportion of patients who achieve SVR
Final Results of ENABLE 1, a Phase 3, Multicenter Study of as an Adjunct for Antiviral Treatment of Hepatitis C Virus -Related Chronic Liver Disease Associated With Thrombocytopenia N. Afdhal; G. Dusheiko;
More informationSpecifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C
Specifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C Zobair M. Younossi, MD, MPH, FACP, FACG Medscape Gastroenterology. 2007; 2007 Medscape Posted 06/01/2007 Introduction
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationIFN-free for Genotype 1 HCV: the current landscape. Prof. Graham R Foster
IFN-free for Genotype 1 HCV: the current landscape Prof. Graham R Foster Wonderful new drugs are coming Poordad F, et al. New Engl J Med 2014; online DOI: 10.1056/NEJMoa1402869. 2 The New Drugs Two treatment
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationBristol-Myers Squibb. HCV Full Development Portfolio Overview. Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013
Bristol-Myers Squibb HCV Full Development Portfolio Overview Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013 1 BMS Agents in Clinical Development: DAAs and INF Lambda Lambda
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationHepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors
Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors Eric Lawitz, MD, AGAF, CPI The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science
More informationBackground: Narlaprevir (SCH )
Once Daily Narlaprevir (SCH 9518) in Combination with Peginterferon alfa-2b/ Ribavirin for Treatment-Naive Patients with Genotype-1 Chronic Hepatitis C: Interim Results from the NEXT-1 Study Vierling J,
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT
ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT Mitchell L Shiffman, MD Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationSYNOPSIS Final Clinical Study Report for Study AI444031
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationSafety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus
Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus JEFFREY NADELSON MD, ALAN EPSTEIN MD, THOMAS SEPE MD BOSTON UNIVERSITY SCHOOL OF MEDICINE ROGER WILLIAMS MEDICAL
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More informationPEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced
Phase 2b Treatment Naïve and Treatment Experienced Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Hézode C, et al. Lancet. 2015 March 30. [Epub ahead of print] PEARL-I: Study Design
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationTreatment with the New Direct Acting Antivirals for Hepatitis C
Treatment with the New Direct Acting Antivirals for Hepatitis C Mary Olson, DNP, ANP-BC Clinical Trials Program Director Weill Cornell Medical College The Center for the Study of Hepatitis C Objectives
More informationHandelsbanken November Bertil Samuelsson VP Discovery Research Rein Piir CFO / IR
Handelsbanken November 18 2009 Bertil Samuelsson VP Discovery Research Rein Piir CFO / IR Pipeline Project Indication(s) Partners/- date of Explorati Optimiz agreement Terms Medivir's markets ve phase
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationTreatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.
Session IV Treatment Options in HCV Relapsers and Nonresponders Raymond T. Chung, M.D. Director of Hepatology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston,
More informationEfficacy and safety of protease inhibitors for sever hepatitis C recurrence after liver transplantation: a first multicentric experience
Efficacy and safety of protease inhibitors for sever hepatitis C recurrence after liver transplantation: a first multicentric experience A. Coilly, B. Roche, J. Dumortier, D. Botta-Fridlund, V. Leroy,
More informationChanging Direction Towards More Effective HCV Treatment
Changing Direction Towards More Effective HCV Treatment By: Prof.Dr.Abdel fattah Hanno Professor of Tropical Medicine Alexandria Faculty of Medicine The most common disease in the world HCV infects almost
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationBest of AASLD 2010 For IAGH. April 2011 Reza Malekzadeh M.D. AGAF Professor of Medicne DDRC/TUMS
Best of AASLD 2010 For IAGH April 2011 Reza Malekzadeh M.D. AGAF Professor of Medicne DDRC/TUMS DAAs Direct-Acting Antivirals Understanding of HCV life cycle Identification of potential targets of antivirals
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationGlecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1
Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1 EXPEDITION-1: Study Features EXPEDITION-1 Trial Design: Open-label, single-arm,
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) PegIFN and RBV remain vital components of HCV therapy-- selected presentations from: Program Disclosure This activity has been planned and
More informationExpress Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
More informationTreatment of chronic hepatitis C in HIV co-infected patients
Treatment of chronic hepatitis C in HIV co-infected patients Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain The most prevalent chronic viral infections in humans HBV
More informationTriple therapy with telaprevir or boceprevir: management of side effects
Triple therapy with telaprevir or boceprevir: management of side effects Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 July August
BRAND NAME Technivie GENERIC NAME Ombitasvir/paritaprevir/ritonavir MANUFACTURER AbbVie, Inc. DATE OF APPROVAL February 27, 2017 PRODUCT LAUNCH DATE Already available on the market REVIEW TYPE Review type
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationNew Therapeutic Strategies: Polymerase Inhibitors
New Therapeutic Strategies: Polymerase Inhibitors 6th Paris Hepatitis Conference 14 th - 15 th January, 2013 Stefan Zeuzem Goethe University Hospital Frankfurt, Germany Direct antiviral targets C E1 E2
More informationMOSCOW CLINICAL SCIENTIFIC CENTER
MOSCOW CLINICAL SCIENTIFIC CENTER Efficacy and safety of Narlaprevir in Russian population of patients with HCV-infection genotype 1: the final results of multicenter randomized placebo-controlled double-blind
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationPegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience
Pegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience E L Seow, PH Robert Ding Island Hospital, Penang, Malaysia. Introduction Hepatitis
More informationStrategies towards cure of HCV infection: a personalized approach. Heiner Wedemeyer Hannover Medical School Hannover, Germany
Strategies towards cure of HCV infection: a personalized approach Heiner Wedemeyer Hannover Medical School Hannover, Germany 1 Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, Biolex,
More informationAbstract 233. Post-treatment follow up. Pawlotsky JM, et al. 63rd AASLD; Boston, MA; November 9-13, 2012:. Abst ALV loading* RVR at W4
Jean-Michel Pawlotsky, Shiv K. Sarin, Graham R. Foster, Cheng-Yuan Peng, Jens Rasenack, Robert Flisiak, Teerha Piratvisuth, Heiner Wedemeyer, Wan-Long Chuang, Wei Zhang and Nikolai V. Naoumov Abstract
More informationSECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM
SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN Background Hepatitis
More informationInterferon-based and interferon-free new treatment options
Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt
More informationSpecial Contribution Highlights of the 2012 American Association for the Study of Liver Diseases Meeting
Special Contribution Highlights of the 20 American Association for the Study of Liver Diseases Meeting Melissa K. Osborn, MD The American Association for the Study of Liver Diseases (AASLD) held its annual
More informationCase #1. Case #1. Case #1: Audience vote VS. The Great Debate: When to Treat HCV in our HIV coinfected patients
Case #1 The Great Debate: When to Treat HCV in our HIV coinfected patients Medical Management of AIDS December, 2012 Moderated by George Beatty,MD 35 year old African American man, CD4 + 450, HIV RNA
More informationHEPATITIS C TREATMENT GUIDANCE
HEPATITIS C TREATMENT GUIDANCE These guidelines have been produced based on the NICE Guidance TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis c and the summaries of product
More informationPierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine
Pierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine Il sottoscritto dichiara di non aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione
More informationInfection with hepatitis C virus (HCV) is a global health concern,
Advances in the Treatment of Hepatitis C Virus Infection Arun B. Jesudian, MD, Maya Gambarin-Gelwan, MD, and Ira M. Jacobson, MD Dr. Jesudian is a Clinical Fellow, Dr. Gambarin-Gelwan is an Assistant Professor
More informationCASE STUDY. Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be?
Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be? CASE STUDY Pham Thi Thu Thuy MD, PhD Ho Chi Minh City Vietnam Serious Adverse
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationReferring to Part of Dossier: Volume: Page:
Synopsis AbbVie Inc. Name of Study Drug: ABT-450, ritonavir, ABT-333, ribavirin Name of Active Ingredient: ABT-450: (2R,6S,12Z,13aS,14aR,16aS)-N- (cyclopropylsulfonyl)-6-{[(5- methylpyrazin-2-yl)carbonyl]amino}-
More informationHepatitis C Treatment
Hepatitis C Treatment Standard of care & Managing advrse events Mohssen Nassiri Toosi, MD A s s o c i a t e P ro f e s s o r Of Internal M e d i c i n e Te h r a n U n i v e r s i t y O f M e d i c a l
More informationImproving Treatment Success Rates for HCV in a Managed Care Setting
Improving Treatment Success Rates for HCV in a Managed Care Setting Bruce R. Bacon, MD James F. King MD Endowed Chair in Gastroenterology Professor of Internal Medicine Division of Gastroenterology and
More informationDeterminants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus
Determinants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus Leah Burke, M.D. 1, Daniel Fierer, M.D. 2, David Cassagnol,
More information2.0 Synopsis. ABT-333 M Clinical Study Report R&D/09/956
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-333 Volume: Name of Active Ingredient: Page: Sodium N-{6-[3-tert-butyl-5-(2,4-
More informationPivotal New England Journal of Medicine papers 2014 Phase 3 Trial data
4 th HCV Therapy Advances Meeting Paris, December 12-13, 14 Pivotal New England Journal of Medicine papers 14 Phase 3 Trial data Stefan Zeuzem, MD University of Frankfurt Germany Disclosures Consultancies:
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationClinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov
Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient Konstantin Zhdanov Genotype 3 in Europe Canada Norway Germany Sweden Czech Republic Poland Approximately 1/3 of HCV-infected patients
More information46th EASL Congress, Berlin, Germany March 30 April 3, 2011 Abstract 66
SILEN-C2: Sustained Virologic Response (SVR) and Safety of BI21335 Combined with Peginterferon Alfa-2a and Ribavirin (P/R) in Chronic HCV Genotype-1 Patients with Non-response To P/R M.S. Sulkowski, M.
More informationInterferon-Based Therapy for Chronic Hepatitis C : Present and Future Perspectives
TAJ December 2008; Volume 21 Number 2 ISSN 1019-8555 The Journal of Teachers Association RMC, Rajshahi Review Article Interferon-Based Therapy for Chronic Hepatitis C : Present and Future Perspectives
More informationOptimal ltherapy in non 1 genotypes:
Optimal ltherapy in non 1 genotypes: genotype 2 and 3 patients Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S. University of Palermo, Italy craxanto@unipa.it Peg IFN alpha plus ribavirin : SVR rate of >80%
More informationUpdates on Current Status of HCV Therapy
Updates on Current Status of HCV Therapy K. Rajender Reddy, MD Professor of Medicine, Professor of Medicine in Surgery, Director of Hepatology and Medical Director of Liver Transplantation University of
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationDevelopments in the Treatment of Hepatitis C: A New Era
Developments in the Treatment of Hepatitis C: A New Era Nancy Love, PharmD, BCPS Memorial Medical Center, Johnstown, PA October 17, 2014 Pharmacist Objectives Summarize the results of clinical trials for
More information